Evidence map›Paper›PMID 20689816›Full record

ArticlePLoS neglected tropical diseases2010

The international limits and population at risk of Plasmodium vivax transmission in 2009.

Carlos A Guerra, Rosalind E Howes, Anand P Patil, Peter W Gething, Thomas P Van Boeckel, William H Temperley, Caroline W Kabaria, Andrew J Tatem, Bui H Manh, Iqbal R F Elyazar and 3 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 292 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
292citing papers in PubMed, 12 pooled it
60.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

292 citing papers in PubMed, 12 syntheses or guidelines pooled it, 462 citations in OpenAlex.

  1. A Systematic Review of the Effects of Temperature onInternational journal of environmental research and public health · 2021
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

232 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 6 countries.

Carlos A GuerraSpatial Ecology and Epidemiology Group, Department of Zoology, University of Oxford, Oxford, UK. carlos.guerraloaiza@zoo.ox.ac.uk
Rosalind E Howes
Anand P Patil
Peter W Gething
Thomas P Van Boeckel
William H Temperley
Caroline W Kabaria
Andrew J Tatem
Bui H Manh
Iqbal R F Elyazar
J Kevin Baird
Robert W Snow
Simon I Hay
University of Oxford · GBKenya Medical Research Institute · KEEijkman Institute for Molecular Biology · IDNuffield Orthopaedic Centre · GBOxford University Clinical Research Unit · VNUniversité Libre de Bruxelles · BEUniversity of Florida · US

Funding

Wellcome Trust 079080Wellcome Trust 079091Wellcome Trust B9RJIXO
6 · The paper itself

Abstract

backgroundA research priority for Plasmodium vivax malaria is to improve our understanding of the spatial distribution of risk and its relationship with the burden of P. vivax disease in human populations. The aim of the research outlined in this article is to provide a contemporary evidence-based map of the global spatial extent of P. vivax malaria, together with estimates of the human population at risk (PAR) of any level of transmission in 2009. METHODOLOGY: The most recent P. vivax case-reporting data that could be obtained for all malaria endemic countries were used to classify risk into three classes: malaria free, unstable (<0.1 case per 1,000 people per annum (p.a.)) and stable (> or =0.1 case per 1,000 p.a.) P. vivax malaria transmission. Risk areas were further constrained using temperature and aridity data based upon their relationship with parasite and vector bionomics. Medical intelligence was used to refine the spatial extent of risk in specific areas where transmission was reported to be absent (e.g., large urban areas and malaria-free islands). The PAR under each level of transmission was then derived by combining the categorical risk map with a high resolution population surface adjusted to 2009. The exclusion of large Duffy negative populations in Africa from the PAR totals was achieved using independent modelling of the gene frequency of this genetic trait. It was estimated that 2.85 billion people were exposed to some risk of P. vivax transmission in 2009, with 57.1% of them living in areas of unstable transmission. The vast majority (2.59 billion, 91.0%) were located in Central and South East (CSE) Asia, whilst the remainder were located in America (0.16 billion, 5.5%) and in the Africa+ region (0.10 billion, 3.5%). Despite evidence of ubiquitous risk of P. vivax infection in Africa, the very high prevalence of Duffy negativity throughout Central and West Africa reduced the PAR estimates substantially.

conclusionsAfter more than a century of development and control, P. vivax remains more widely distributed than P. falciparum and is a potential cause of morbidity and mortality amongst the 2.85 billion people living at risk of infection, the majority of whom are in the tropical belt of CSE Asia. The probability of infection is reduced massively across Africa by the frequency of the Duffy negative trait, but transmission does occur on the continent and is a concern for Duffy positive locals and travellers. The final map provides the spatial limits on which the endemicity of P. vivax transmission can be mapped to support future cartographic-based burden estimations.

Indexed as

GeographyPopulationAfricaAmericasAsiaHumansMalaria, VivaxRisk Assessment

Identifiers

PMID20689816
PMCPMC2914753
OpenAlexW2097432479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.